How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.

What services does ImpriMed offer?

ImpriMed offers personalized medicine services to help you diagnose and treat canine lymphoma or leukemia. (Click to read more)

Which cancers can I use ImpriMed for? or What type of cancer does ImpriMed predict?

Currently, our services are for canine lymphoma and leukemia. We will be expanding our services to other species and other blood / lymphoid cancers in the near future.

What type of sample is needed – just aspirates and a typical flow sample?

We need about 10 million cancer cells to run the full chemosensitivity panel so we ask that you conduct an aggressive woodpecker style FNA, poking as many nodes as possible and putting the cells into our proprietary media tubes (ensures we receive live cells), then of course we need a whole blood sample (2mL).

What's the breakdown of sensitivity of your PARR for canine B and T cell lymphomas?

PARR Sensitivity for B-Cell is 90.71% and for T-Cell is 85.45%.

Is it wise to eliminate a certain chemotherapy drug based on the test results or should there be other factors that need to be considered in this decision?